Cuorips Past Earnings Performance
Past criteria checks 0/6
Cuorips's earnings have been declining at an average annual rate of -23.1%, while the Biotechs industry saw earnings growing at 16.7% annually. Revenues have been growing at an average rate of 48% per year.
Key information
-23.1%
Earnings growth rate
9.1%
EPS growth rate
Biotechs Industry Growth | 31.9% |
Revenue growth rate | 48.0% |
Return on equity | -10.6% |
Net Margin | -2,747.8% |
Next Earnings Update | 13 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Cuorips makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 23 | -632 | 598 | 0 |
31 Dec 23 | 40 | -598 | 405 | 168 |
31 Mar 23 | 38 | -452 | 302 | 168 |
31 Mar 22 | 13 | -375 | 383 | 0 |
Quality Earnings: 4894 is currently unprofitable.
Growing Profit Margin: 4894 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 4894's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 4894's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4894 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-0.8%).
Return on Equity
High ROE: 4894 has a negative Return on Equity (-10.57%), as it is currently unprofitable.